HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings

This article was originally published in The Tan Sheet

Executive Summary

A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity

You may also be interested in...

FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court

An appeals court's dismissal of Apotex' lawsuit against FDA relating to patent listings affirms a key provision in the final rule reforming Hatch/Waxman

FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule

Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule

GPhA Sees Generic Legislation Passing House After S 812 Clears Senate

The Generic Pharmaceutical Association appears confident it will not have to make significant concessions to move S 812 through the House

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts